

Supplementary information

Table S1. Other metals with antibacterial potential.

Metal	Observed Activity	References
Bismuth	<ul style="list-style-type: none"> • Bi(III) exhibits low toxicity against humans and potent toxicity against bacteria. • <i>H. pylori</i> appears particularly susceptible to three bismuth drugs: ranitidine bismuth citrate (Pylorid), colloidal bismuth subcitrate (CBS, De-Nol), and bismuth subsalicylate (Pepto-Bismol) • Bi(III) and CBS identified as metallo-β lactamase inhibitors. 	[26, 193]
Iridium	<ul style="list-style-type: none"> • Ir(III) complexes shown bacteriostatic activity • Good antimicrobial potential • High cost of element and high dosage required for antibacterial effect, thus not a primary resource 	[26]
Iron	<ul style="list-style-type: none"> • Moderate antibacterial activity against the Gram-positive bacteria <i>S. aureus</i> • Inactive against Gram-negative <i>E. coli</i> and <i>P. aeruginosa</i> • More studies required to determine <i>in vitro</i> and <i>in vivo</i> efficacy and toxicity 	[194]
Palladium	<ul style="list-style-type: none"> • Antibacterial activity observed against <i>E. faecalis</i>, <i>S. aureus</i>, <i>E. coli</i>, <i>K. pneumonia</i>, and <i>P. aeruginosa</i> • Proposed antibacterial activity caused by binding with DNA and protein • More studies required to determine <i>in vitro</i> and <i>in vivo</i> efficacy and toxicity 	[195, 196]
Platinum	<ul style="list-style-type: none"> • Bactericidal activity, inducing bacterial filamentation and lysis in lysogenic bacteria • Proposed antibacterial activity caused by interaction with DNA 	[197]
Rhenium	<ul style="list-style-type: none"> • Antimicrobial activity not well researched • Promising activity against Gram-positive bacteria in particular • Lack of <i>in vivo</i> data, requires further research 	[26]

Metal	Observed Activity	References
Rhodium	<ul style="list-style-type: none"> • Bacteriostatic effect against the Gram-positive bacterium <i>S. pneumoniae</i> without significant cytotoxic side-effect on host cell <i>in vitro</i> • Affects bacterial metal ion binding and metabolic pathways • More studies required to determine <i>in vitro</i> and <i>in vivo</i> efficacy and toxicity 	[198]
Ruthenium	<ul style="list-style-type: none"> • Bactericidal activity • Labile ruthenium complexes bind nucleic acids through ligand exchange reactions • Inert ruthenium compounds, generally bearing one or more polypyridyl ligand(s), can bind DNA and RNA through intercalation • Remarkable antimicrobial activity shown <i>in vitro</i> • Rapid clearance following IV administration reduces efficacy of compounds administered <i>in vivo</i>, likely better for topical administration • Lower propensity to induce resistance in <i>Streptococcus pyogenes</i> than penicillin • Further efficacy experiments required to determine <i>in vivo</i> efficacy 	[26]
Tellurium	<ul style="list-style-type: none"> • Antibacterial activity demonstrated against <i>E. coli</i>, <i>E. cloacae</i>, and <i>P. aeruginosa</i> • Te ions taken up by bacteria as if amino acids, replacing sulfur atom to form Tellurium-cysteine and Tellurium-methionine • More studies required to determine <i>in vitro</i> and <i>in vivo</i> efficacy and toxicity 	[199-201]

Table S2. MIC values of auranofin analogues **(11)** to **(16)** tested against a series of Gram-negative and Gram-positive bacterial strains (μM).

	Gram-negative					Gram-Positive	
	<i>A. baumannii</i>	<i>P. Aeruginosa</i>	<i>E. cloacae</i>	<i>K. pneumoniae</i>	<i>E. Coli</i>	<i>S. aureus</i>	<i>E. faecium</i>
(11)	24	189	47	189	12	0.04-0.09	0.09
(12)	15-29	464	116	464	4-7	0.02	0.05-0.1
(13)	4-17	>547	4-9	34	9	0.3-0.5	0.3-0.5
(14)	9-19	>547	4	34	9	0.3	0.3-0.5
(15)	8-16	>503	8-16	31	8-31	0.5	0.2-0.5
(16)	3-6	23-91	3	11	1-6	0.3	0.3

References

193. **Nazari P, Dowlatabadi-Bazaz R, Mofid MR, Pourmand MR, Daryani NE et al.** The Antimicrobial Effects and Metabolomic Footprinting of Carboxyl-Capped Bismuth Nanoparticles Against *Helicobacter pylori*. *Applied Biochemistry and Biotechnology* 2014;172(2):570-579.
194. **Patra M, Gasser G, Wenzel M, Merz K, Bandow JE et al.** Synthesis and Biological Evaluation of Ferrocene-Containing Bioorganometallics Inspired by the Antibiotic Platensimycin Lead Structure. *Organometallics* 2010;29(19):4312-4319.
195. **Kalaivani P, Prabhakaran R, Ramachandran E, Dallemer F, Paramaguru G et al.** Influence of terminal substitution on structural, DNA, Protein binding, anticancer and antibacterial activities of palladium(ii) complexes containing 3-methoxy salicylaldehyde-4(N) substituted thiosemicarbazones. *Dalton Transactions*, 10.1039/C1DT11838B 2012;41(8):2486-2499.
196. **Kalaivani P, Prabhakaran R, Dallemer F, Poornima P, Vaishnavi E et al.** DNA, protein binding, cytotoxicity, cellular uptake and antibacterial activities of new palladium(ii) complexes of thiosemicarbazone ligands: effects of substitution on biological activity. *Metallomics*, 10.1039/C1MT00144B 2012;4(1):101-113.
197. **Johnstone TC, Alexander SM, Lin W, Lippard SJ.** Effects of Monofunctional Platinum Agents on Bacterial Growth: A Retrospective Study. *Journal of the American Chemical Society* 2014;136(1):116-118.
198. **Yang X-Y, Xu J-Y, Meng M, Li N, Liu C-Y et al.** Dirhodium (II) complex interferes with iron-transport system to exert antibacterial action against *Streptococcus pneumoniae*. *Journal of Proteomics* 2019;194:160-167.
199. **Kalechman Y, Shani A, Sotnik-Barkai I, Albeck M, Sredni B.** The Protective Role of Ammonium Trichloro(dioxoethylene-*O,O'*) tellurate in Combination with Several Cytotoxic Drugs Acting by Different Mechanisms of Action. *Cancer Research* 1993;53(24):5962-5969.
200. **Ramadan SE, Razak AA, Ragab AM, El-Meleigy M.** Incorporation of tellurium into amino acids and proteins in a tellurium-tolerant fungi. *Biological Trace Element Research* 1989;20(3):225.
201. **D'Arcy K, Doyle AP, Kavanagh K, Ronconi L, Fresch B et al.** Stability of antibacterial Te(IV) compounds: A combined experimental and computational study. *Journal of Inorganic Biochemistry* 2019;198:110719.